<DOC>
	<DOCNO>NCT01799798</DOCNO>
	<brief_summary>Pilot study assess efficacy therapy RANKL-antibody denosumab child 5-10 year age mutation COL1A1 COL1A2 lead Osteogenesis imperfecta . Efficacy assess DXA measurement lumbar spine areal bone mineral density ( BMD ) frequently use parameter trial investigate osteoporosis . The hypothesis study : Osteoclastic activity increase OI could reduce inhibition osteoclast maturation . Denosumab inhibit maturation osteoclast inhibit RANKL . BMD could increase 36 week treatment course denosumab measure 48 week .</brief_summary>
	<brief_title>Translational Therapy Patients With Osteogenesis Imperfecta - A Pilot Trial Treatment With Rankl-Antibody Denosumab</brief_title>
	<detailed_description />
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Inclusion Criteria Male female subject 5 year 10 year age molecular proven Osteogenesis imperfecta ( COL1A1/A2 mutation ) Subjects must treat minimum 2 year bisphosphonates prior study entry Hypocalcemia ( &lt; 1.03 mmol/l ionized Calcium ) Subjects reduced renal function ( estimate GFR ( Schwartz formula ) &lt; 30ml/min/1.73m2 ) Any abnormal finding physical examination laboratory evaluation , opinion investigator indicative disease would compromise safety patient get denosumab s.c .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Osteogenesis imperfecta</keyword>
	<keyword>COL1A1/A2</keyword>
	<keyword>Denosumab</keyword>
	<keyword>Bisphosphonates</keyword>
	<keyword>Children</keyword>
	<keyword>Areal bone mineral density</keyword>
</DOC>